LTZ Therapeutics Secures $40 Million in Oversubscribed Series A+ Financing Led by Zoo Capital to Advance Myeloid Engager Platform

Investment Circle (ID: pedaily2012) April 24th, by reporter, LTZ Therapeutics (referred to as "LTZ" or "the Company") announced the completion of an oversubscribedSeries A+ Financing, successfully raised$40 million. This round of financing was led by new investorsMorningside Ventures Leads Investment。BlueRun Ventures China, Morningside Ventures, Unicorn Capital Partners Limited, Follicular Lymphoma Innovation Research InstituteParticipate together. Existing shareholdersLapamCapital, GL VenturesContinued investment. Since its establishment in 2022, LTZ has raised a total of 90 million US dollars.

LTZ Therapeutics Focuses on Unmet Clinical Needs in Major Disease Areas such as Cancer and Autoimmune Diseases, Committed to Developing Novel Immunotherapies Based on the "Myeloid Engager Platform" Technology. The newly raised funds from this round will be mainly used to support the Phase I clinical study of the company’s first candidate drug, LTZ-301, advance the IND application preparations for the second candidate drug, LTZ-232, targeting pan-solid tumor indications, and also facilitate the research and development of other early-stage projects and the expansion of the global team.

BlueRun Ventures ChinaLTZ Therapeutics is a globally leading myeloid cell engager company. The company's innovative platform can effectively utilize and activate myeloid cells enriched in tissues as effector cells to achieve effective and safe killing of target cells, which has been validated in various clinically relevant models. The company’s leading pipeline has completed the U.S. IND, and it is expected to bring breakthrough therapeutic effects in the fields of oncology and autoimmune diseases in the future. We are optimistic about LTZ's development potential in the global market.

Dr. Jinze Li, Founder and CEO of LTZ TherapeuticsSaid: "We sincerely thank new and existing investors and partners for their strong support. This will strongly drive our core pipeline into the next stage of clinical development. Among them, the fastest progressing LTZ-301 is aFor the treatment of relapsed or refractory non-Hodgkin lymphoma (r/r NHL). With its IND application recently approved by the U.S. FDA, the company looks forward to officially launching and exploring the broad application prospects of our proprietary technology platform in pan-tumor and autoimmune disease fields."

LTZ’s R&D Strategy Deeply Integrates "Reverse Translational Science" with a Profound Understanding of Tumor Microenvironment (TME) Biology, Particularly Myeloid Cell Biology. Macrophages are among the most abundant immune cell populations in the tumor microenvironment across various hematological malignancies and solid tumors. Therefore, effectively and safely harnessing macrophages to kill target cells offers significant therapeutic potential and clinical value for a wide range of indications. LTZ is independently developing a novel "Myeloid Cell Engager" technology platform aimed at enhancing the phagocytic function of macrophages and monocytes under different polarization states, establishing a broad-spectrum immunotherapy barrier.